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ABSTRACT: Bifunctional degrader molecules, known as
proteolysis-targeting chimeras (PROTACs), function by
recruiting a target to an E3 ligase, forming a target/
PROTAC/ligase ternary complex. Despite the importance of
this key intermediate species, no detailed validation of a
method to directly determine binding parameters for ternary
complex kinetics has been reported, and it remains to be
addressed whether tuning the kinetics of PROTAC ternary
complexes may be an eﬀective strategy to improve the
eﬃciency of targeted protein degradation. Here, we develop
an SPR-based assay to quantify the stability of PROTAC-
induced ternary complexes by measuring for the ﬁrst time the
kinetics of their formation and dissociation in vitro using puriﬁed proteins. We benchmark our assay using four PROTACs that
target the bromodomains (BDs) of bromodomain and extraterminal domain proteins Brd2, Brd3, and Brd4 to the von Hippel−
Lindau E3 ligase (VHL). We reveal marked diﬀerences in ternary complex oﬀ-rates for diﬀerent PROTACs that exhibit either
positive or negative cooperativity for ternary complex formation relative to binary binding. The positively cooperative degrader
MZ1 forms comparatively stable and long-lived ternary complexes with either Brd4BD2 or Brd2BD2 and VHL. Equivalent
complexes with Brd3BD2 are destabilized due to a single amino acid diﬀerence (Glu/Gly swap) present in the bromodomain. We
observe that this diﬀerence in ternary complex dissociative half-life correlates to a greater initial rate of intracellular degradation
of Brd2 and Brd4 relative to Brd3. These ﬁndings establish a novel assay to measure the kinetics of PROTAC ternary complexes
and elucidate the important kinetic parameters that drive eﬀective target degradation.
Proteolysis-targeting chimeras (PROTACs) are bivalentmolecules consisting of ligands for each of a target protein
and an E3 ligase, joined via a linker.1,2 PROTAC behavior can
be modeled by three-body binding equilibria.3 Formation of a
target/PROTAC/ligase ternary complex triggers proximity-
dependent target protein ubiquitylation and degradation via
the ubiquitin−proteasome system.2,4 PROTAC drug discovery
is rapidly advancing in both academia and industry, fuelled by
both improvement in drug-like properties and broader
recognition of mechanistic advantages of degradation over
inhibition.1,5,6 PROTACs oﬀer potential for improved
selectivity beyond that of the constituent target ligand by
harnessing additional stabilizing or destabilizing de novo
protein−protein or protein−linker interactions formed via
the ternary complex.2,7−9 Thus, in the context of a PROTAC
ternary complex (ABC), the binding aﬃnity of the PROTAC
“B” to one protein partner “C” (binary binding) may be
enhanced or reduced by the presence of the second protein
partner “A” (ternary binding). This eﬀect can be quantiﬁed in
terms of a “cooperativity” (α) factor, deﬁned as the ratio of
binary and ternary dissociation constants for PROTAC
binding to C (α = KD
binary/KD
ternary) (Figure 1A).2 Coopera-
tivity may be described as “positive” (α > 1, enhanced ternary
binding aﬃnity relative to binary, thus further stabilizing the
complex), “negative” (α < 1, reduced ternary binding aﬃnity
relative to binary, thus destabilizing the complex) or “non-
cooperative” (α = 1, no change in binding aﬃnity for C due to
the presence of A). Developing new tools to understand
cooperativity and avidity eﬀects and ternary complex stability
in PROTAC design is thus of signiﬁcant interest. Although
functional degraders can be generated in the absence of
positive cooperativity,8,10 mounting evidence suggests enhanc-
ing cooperativity and stability of ternary complexes could be an
eﬀective strategy in PROTAC design.11−13 As bifunctional
molecules, PROTACs are subject to a well-recognized “hook
eﬀect”, whereby at high PROTAC concentrations, binary
interactions may outcompete ternary complex formation.5,14 3
Cooperativity is expected to counter this “hook eﬀect” often
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exhibited by bifunctional molecules, thereby widening the
concentration window for PROTAC activity and could also
enable the use of weaker-aﬃnity ligands.15,16
There is now a growing literature of complementary
methods to measure formation of PROTAC ternary
complexes, oﬀering diﬀerent relative strengths and weaknesses
(reviewed more comprehensively elsewhere).9 A number of
steady-state methods have been described to measure ternary
complex formation, cooperativity, or both. These include pull-
down assays15 and proximity-based assays (e.g., AlphaScreen/
AlphaLISA, time-resolved ﬂuorescence energy transfer (TR-
FRET)) to measure relative ternary complex formation at
steady state as a function of PROTAC concentration.2,13,15,17
Such assays can oﬀer high throughput but require the labeling
of both target and E3 ligase proteins, and the readout of
ternary complex formation is indirect and semi-quantitative,
owing to context-speciﬁc eﬀects that may potentially aﬀect
assay measurement and confound comparison between
PROTACs (e.g., eﬀects due to target protein identity, relative
protein orientation in the ternary complex, concentrations of
proteins used in the assay, and the intrinsic absorbance or
ﬂuorescence of PROTACs). Cooperativity assays based on
competitive binding (e.g., ﬂuorescence polarization, to measure
PROTAC binding to VHL in the presence or absence of target
protein) have also been used to determine binding and
cooperativity of PROTACs.11 ITC has also been used for label-
free direct quantiﬁcation of thermodynamic and binding
parameters of PROTACs (for both binary and ternary complex
formation),2,10,12 however, it is relatively more resource-
intensive and lower throughput. Notably, none of these assays
oﬀer kinetic resolution. Recently, promising cell-based assays
have been reported that enable real-time kinetic monitoring of
PROTAC ternary complexes in cells, including the kinetic
EGFP separation of phase-based protein interaction reporter
(SPPIER)18 and kinetic bioluminescence resonance energy
transfer (BRET)19 approaches. These cell-based methods
enable the use of full-length proteins, albeit with the caveats
that proteins must still be labeled (potentially giving rise to
assay-speciﬁc eﬀects described earlier), and the readout of
ternary complex formation over time is still indirect.
Promisingly, the ratiometric nature of BRET enables
quantitative measurement.19 However, the readout in such
cell-based assays may also be strongly aﬀected by compound-
speciﬁc factors, including variable cell permeability or non-
speciﬁc binding to cellular components as well as the potential
general complication of target protein degradation at later time
points if the normal proteosomal pathway has not been
disrupted either genetically or chemically. It is thus also
desirable to have well-validated, quantitative biophysical assays
to measure PROTAC ternary complex kinetics in vitro using
puriﬁed proteins.
We were thus interested in exploring surface plasmon
resonance (SPR) as a suitable label-free technique to monitor
the kinetics of PROTAC-induced ternary complexes, the
required intermediate species in the mechanism.4 Herein, we
develop the ﬁrst SPR-based assay to quantitatively measure the
kinetics of ternary complex formation and dissociation, which
we use to characterize the lifetime of ternary complexes
composed of bromodomain-containing target proteins, PRO-
TACs, and the von Hippel−Lindau E3 ligase (VHL).
SPR has previously been utilized to characterize three-body
binding systems (including complexes composed of protein,
DNA, and small molecules),20−23 which can be experimentally
involving due to the complex nature of the binding equilibria.3
We sought a general-purpose and conceptually simple assay
format to study PROTAC ternary complexes. Importantly, we
recognized for bivalent molecules that the “hook eﬀect” would
preclude use of saturating concentrations of PROTAC in the
running buﬀer. We reasoned that by immobilizing the E3
Figure 1. Schematic and binding data illustrating our SPR approach
for measuring binding kinetics and determining cooperativity (α) for
PROTAC binary and ternary complex formation. (A) Ternary
binding equilibria, as occurs for bivalent molecules (such as
PROTACs binding to two proteins, a target “A” and an E3 ligase
“C”) may involve cooperativity eﬀects, whereby the aﬃnity of the
bivalent molecule to one protein (binary complex formation) may be
enhanced or decreased when it is already bound to the second protein
(ternary complex formation). This may result from additional
interactions present in the ternary complex, such as induced de
novo protein−protein interactions (PPIs). This eﬀect can be
represented by a cooperativity factor (α), where α = KD
binary/KD
ternary.
(B) To measure the kinetics of PROTAC ternary complexes and
determine cooperativity eﬀects, we have developed an SPR assay in
which we immobilized the E3 ligase (in our case, VHL) onto a sensor
chip and measured binding of a PROTAC in either the (i) absence
(binary binding) or (ii) presence (ternary binding) of near-saturating
concentrations of the target protein (in our case, a bromodomain and
extraterminal domain). (C) Representative SPR binding data are
shown using this assay for (i) MZ1 or (ii) the MZ1:Brd4BD2 complex
binding to immobilized VHL. Binary and ternary binding experiments
were performed at 285.15 K in multicycle kinetic format and 298.15 K
in single-cycle kinetic (SCK) format, respectively. For each sensor-
gram, values shown represent ﬁtted dissociation constants for binary
or ternary complex formation (KD
binary and KD
ternary, respectively),
dissociative half-life of the ternary complex (t1/2) (calculated as t1/2 =
ln2/koff), and cooperativity factor (α) (calculated as α = KD
binary/
KD
ternary).
ACS Chemical Biology Letters
DOI: 10.1021/acschembio.9b00092
ACS Chem. Biol. 2019, 14, 361−368
362
ligase, a single sensor surface might be utilized to measure
diverse PROTAC/target combinations. To improve uniform
presentation on the chip surface, we designed a VHL/
ElonginB/ElonginC (VCB) construct harboring an AviTag
sequence C-terminal to ElonginB for site-speciﬁc biotinylation
(hereafter “biotin−VHL”).24,25
Using a Biacore T200 SPR instrument and streptavidin-
immobilized biotin−VHL, we measured the kinetics and
aﬃnity of VHL binding for a concentration series of either
PROTAC alone (to form a binary complex with VHL, KD
binary)
or PROTAC pre-incubated with near-saturating concentra-
tions of target protein (to form a ternary complex with VHL,
KD
ternary; Figure 1). To achieve near-saturation, the minimum
concentration of target protein used was 2 μM (corresponding
to approximately a 20- to 50-fold excess of binary KD of the
PROTAC for the target protein to ensure at equilibrium ≥95−
98% formation of binary complex) (refer to Figures S1 and
S2). Experiments were performed in either multicycle (binary)
or single-cycle (ternary) format without regeneration to ensure
a maximally stable surface and reduce experimental run-times
for PROTAC/BD complexes exhibiting slow dissociation
kinetics (refer to Figure S3).26 Doubly referenced replicate
data were ﬁtted globally (over multiple surface densities where
applicable) to a 1:1 Langmuir binding model incorporating a
parameter for mass-transfer eﬀects to determine kinetic
constants (kon, koff) from which dissociation constants were
calculated (KD = koff/kon). Cooperativity (α) was calculated as
the ratio KD
binary/KD
ternary.
To benchmark the assay, we utilized the PROTAC MZ1,
which forms a highly cooperative ternary complex with VHL
and the second bromodomain (BD2) of Brd4 (Brd4BD2) that
we have previously characterized both biophysically and
structurally.2,7,10 In addition to MZ1, we selected three other
PROTACs with ITC-measured aﬃnities for ternary complex
formation with VHL/bromodomain and extraterminal domain
(BET) bromodomains (see Chart 1).2,10 Combined, these
encompass a range of both binary binding aﬃnities and ternary
complex cooperativities (both positive and negative). This set
includes MZ1 and AT1, two positively cooperative PROTACs
based on a triazolodiazepine BET inhibitor JQ1 (ligand A,
Chart 1), as well as MZP55 and MZP61, two negatively
cooperative PROTACs based on a more potent tetrahydroi-
soquinolone BET inhibitor I-BET726 (ligand B, Chart 1).
SPR binding studies were performed with MZ1, AT1,
MZP55, and MZP61 alone (binary) or in complex with
Brd4BD2 as a representative BET bromodomain (ternary) and
binding data compared with the ITC-obtained values (Tables
1 and S1 and Figures S1−S4).2,10 For MZ1, ternary complex
formation was also measured with other BET bromodomains
(Table 1 and Figure 2). No interaction was observed between
VHL and Brd4BD2 in the absence of PROTAC (Figure S2). For
the panel of PROTACs evaluated, the measured KD values for
binary and ternary complexes, as well as the calculated values
for the both cooperativity and change in complex stability
(ΔΔG), were remarkably comparable using either ITC or SPR
(Table 1). For MZP61 and MZP55, some nonspeciﬁc eﬀects
were observed for binary binding to VHL (Figure S4); in the
case of MZP61, these eﬀects were suﬃciently pronounced as to
preclude accurate kinetic ﬁtting, so steady-state ﬁtting was used
to estimate KD
binary.
Relative to the binary equilibria, the VHL/MZ1/Brd4BD2
ternary complex displayed both a faster kon and a slower koff,
leading to the tighter KD
ternary and signiﬁcant positive
cooperativity (α ≈ 20) (see Figure 1C and Tables 1 and
S1). As anticipated, the VHL/AT1/Brd4BD2 ternary complex
also exhibited positive cooperativity (α ≈ 5). In stark contrast,
ternary complexes formed by either of MZP55 and MZP61
with Brd4BD2 had very fast dissociation kinetics (>80-fold faster
than the VHL/MZ1/Brd4BD2 complex) reﬂecting overall
negative cooperativity, with the ternary complex exhibiting
the most negative cooperativity (relative to the binary binding
to VHL) being that formed by MZP61 (Table S1 and Figure
S4). Analogous experiments were conducted in a reversed
format using immobilized Brd4BD2 and PROTAC in solution in
the absence or presence of excess VHL. Although quantitative
ﬁtting of these ternary data was not possible, qualitatively, the
sensorgrams reﬂected the same trends already described for the
standard format (Figure S6). While we have shown that both
the ITC and SPR approaches are complementary and yield
similar values, the notable advantages of our SPR method are
increased throughput and yielding kinetic information,
including estimates of the lifetime of the ternary complex.
This information is invaluable to better understand PROTAC
function and ternary complex stability in an enzymatic
context,4 analogously to how quantiﬁcation of inhibitor
residence time has helped to understand pharmacological
function in certain occupancy-driven small-molecule con-
texts.27,28
MZ1 has been shown to degrade Brd4 more potently than
Brd2 or Brd3 (despite near-equipotent binding of the
constituent warhead ligand to all BET bromodomains),7,10,19
resulting from the high thermodynamic stability of the VCB/
MZ1/Brd4BD2 complex.2 This data suggested varying levels of
cooperativity for MZ1 VHL/PROTAC/BD ternary complexes.
Moreover, literature data from us using biophysical methods2
and others using cellular degradation assays,8 as well as our
own FP data (vide inf ra) are consistent with the MZ1
mediated degradation of BET proteins being driven by
complex formation with the BD2s. In an eﬀort to better
understand on a kinetic level the basis for apparent diﬀerences
in cooperativity, we sought to quantify the overall kinetics of
VHL/PROTAC/BD ternary complexes for each of the
diﬀerent BET bromodomains (Figures 2, S7, and S8 and
Tables 1 and S2). Ternary complexes consisting of VHL, MZ1,
and the ﬁrst bromodomain (BD1) of either Brd2, Brd3, or
Brd4 all displayed very fast dissociation kinetics (t1/2 < 1 s),
Chart 1. PROTACs Utilized in This Study
ACS Chemical Biology Letters
DOI: 10.1021/acschembio.9b00092
ACS Chem. Biol. 2019, 14, 361−368
363
resulting overall in either low positive cooperativity or no
cooperativity (α ≈ 1). In the case of the second
bromodomains (BD2), ternary complexes instead exhibited
much-slower dissociation kinetics (up to 800 slower for a BD2
Table 1. Binding of PROTACs or PROTAC/BD Complexes to Immobilized VHL (SPR) and Comparison with ITC Data
SPR (VHL)a ITC (VHL)2,10
PROTAC + target KD (nM) kon (M
−1 s−1) × 105 koff (s
−1) t1/2 (s) α ΔΔGb (kcal/mol) KD (nM) α ΔΔGb (kcal/mol)
MZ1 binary − 29 7 0.019 43 − − 66d − −
ternary Brd2BD1 23 3900 >1 <0.7 1.3 −0.1 24d 2.9d −0.6d
ternary Brd3BD1 12 1400 >1 <0.7 2.4 −0.4 19d 3.5d −0.8d
ternary Brd4BD1 30 700 >1 <0.7 0.9 +0.1 28d 2.3d −0.5d
ternary Brd2BD2 0.9 120 0.01 67.4 32 −2.0 28d 2.3d −0.5d
ternary Brd3BD2 8 160 0.12 6 3.6 −0.7 7d 10.7d −1.5d
ternary Brd4BD2 1 59 0.006 130 22 −1.7 3.7d 17.8d −1.7d
AT1 binary − 110 6 0.06 17 − − 335d − −
ternary Brd4BD2 24 14 0.03 − 4.7 −0.8 46d 7.3d −1.2d
MZP55 binary − 69 2.7 0.015 48 − − 109e − −
ternary Brd4BD2 185 27 0.47 1 0.4 +0.7 183e 0.6e +0.3e
MZP61 binary − 104c − − − − − 116e − −
ternary Brd4BD2 465 30 1 1 0.2 +1.0 781e 0.1e +1.1e
aRefer to Tables S1 and S2 for full details (including errors). All binary binding experiments using immobilized VHL were performed at 285.15 K
in multicycle kinetic format, whereas ternary binding experiments were performed at 298.15 K in single-cycle kinetic (SCK) format (to decrease
experimental run times for complexes that dissociated slowly). For ease of presentation and comparison, SCK data were overlaid in a format similar
with multicycle kinetic data (as described in Figure S3). Representative sensorgrams for binary and ternary experiments are shown in Figures S4
and S7. For SPR data, listed values were calculated from ﬁtted kinetic data as follows: dissociation constant (KD = koff/kon), dissociative half-life (t1/2
= ln2/koff), and cooperativity (α = KD
binary/KD
ternary); diﬀerence in standard Gibbs free energy change between ternary and binary binding (ΔΔG =
ΔGternary − ΔGbinary) were given for which, in each case, ΔG = RTlnKD, where KD is the appropriate binary or ternary dissociation constant (in M,
although in reality, it is dimensionless), R is the ideal gas constant (R = 1.9872 cal.K−1 mol−1), and T is the experimental temperature (in K). For
MZP55 and MZP61 nonspeciﬁc eﬀects were observed during injection; hence, these binary KD values and kinetic constants may be considered
approximate. bDiﬀerence in standard Gibbs free energy change between ternary and binary binding (ΔΔG = ΔGternary − ΔGbinary); calculated for
ITC data as described for SPR data. cFitting by steady-state aﬃnity. dLiterature value (ref 2). eLiterature value (ref 10). Note: the oﬀ rates for
VHL/MZ1/BD1s are too fast to be quantiﬁed using a Biacore T200 so are reported as above the upper limit of the instrument's typical working
range (koff >1 s
−1).
Figure 2. (A) Diagram of BET proteins Brd2, Brd3, and Brd4, showing individual bromodomains (BDs) used in this study; these BET proteins
exhibit diﬀerent degradation proﬁles in response to MZ1 treatment.2,7 To study the relative kinetics and cooperativity for ternary complex
formation with MZ1 and VHL, MZ1/BD complexes were prepared and binding to immobilized VHL measured by SPR. (B) SPR sensorgrams for
diﬀerent MZ1/BD complexes reveal marked diﬀerences in binding kinetics, particularly VHL/MZ1/Brd2BD2 and VHL/MZ1/Brd4BD2 ternary
complexes dissociated relatively slowly (as a result of the high positive cooperativity, α, and greater complex stability). Ternary binding experiments
were performed at 298.15 K in single-cycle kinetic (SCK) format. For each sensorgram, values shown represent ﬁtted dissociation constants for
ternary complex formation (KD
ternary), dissociative half-life of the ternary complex (t1/2) (calculated as t1/2 = ln2/koff) and cooperativity factor (α)
(calculated as α = KD
binary/KD
ternary).
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compared to a BD1 in the case of Brd2; see Table 1),
consistent with the known degradation-driving complexes
(with BD2s) being the more-stable and longer-lived com-
plexes. Crucially, we were struck by the signiﬁcantly longer
ternary half-life of the VCB/MZ1/BD ternary complexes with
Brd2BD2 and Brd4BD2 (t1/2 ≈ 70 and 130 s, respectively)
relative to the more short-lived ternary complex with Brd3BD2
(t1/2 ≈ 6 s).
Overlay of crystal structures of either Brd2BD2 (PDB: 3ONI)
or Brd3BD2 (PDB: 3S92) in complex with JQ1 and the VCB/
MZ1/Brd4BD2 structure (PDB: 5T35),2 suggested that ternary
complex formation could be inﬂuenced by a single amino acid
residue diﬀerence (Glu344 within the ZA loop of Brd3BD2,
which corresponds to Gly382 and Gly386 in Brd2BD2 and
Brd4BD2) (Figure 3A). In an equivalent VCB/MZ1/Brd3BD2
complex, the side-chain of Glu344 would induce severe steric
clash with the VHL/MZ1 portion of the complex, leading to
destabilization. We therefore generated reciprocal point
mutant swaps (Figure 3B) and measured ternary complex
formation by SPR with MZ1 or AT1. In all cases, the resulting
SPR binding proﬁles reﬂected the eﬀect predicted for the point
mutation. The G-to-E point mutation in Brd4BD2 or Brd2BD2
shortened the ternary complex half-life, decreasing coopera-
tivity and complex stability; while the reverse point mutation in
Brd3BD2 extended the ternary half-life to resemble the proﬁle
for Brd4BD2 and, correspondingly, increased cooperativity and
stability (Figures 3C and S9 and Table S2). As a cross-
validation, we evaluated these complexes in a competitive
ﬂuorescence polarization (FP) assay; measuring VHL binding
of PROTAC or a PROTAC:BD binary complex via the
displacement of a ﬂuorescent HIF-1α peptide probe (Table S2
and Figure S10). Good correlation was observed between SPR-
ﬁtted dissociation constants (KD) and FP-derived inhibition
constants (KI) (Figure 4A). Cooperativity values were also
comparable using either method (Table S2). Together, these
results underscore the robustness of our SPR approach and
further support the conclusion that the described VCB/MZ1/
Brd4BD2 structure (PDB: 5T35)2 reﬂects the predominant
(long-lived) species present in solution.
These SPR data illustrate kinetically a mechanistic diﬀerence
between diﬀerent PROTAC “archetypes”.10 On the one hand,
MZP55 and MZP61 are PROTACs with high binary target
aﬃnity (for Brd4) but low or negative cooperativity (Figures
S4 and S6), thus likely forming highly populated binary
complexes but a very transient ternary complex. On the other
hand, MZ1 and AT1 exhibit weaker binary target aﬃnity (for
Brd4), but this is compensated for in the case of Brd4BD2 by
signiﬁcant positive cooperativity (to form stable ternary
complexes). This latter case is predicted to ﬁt a “rapid
equilibrium” kinetics model, where a rate-limiting ubiquitina-
tion step is dependent on the concentration of PROTAC-
induced ternary complex.4 In this regime, an extension in
ternary complex stability (and, hence, lifetime) would be
expected to increase rates of target protein ubiquitination and
degradation, particularly at early time points prior to
countervailing factors such as protein resynthesis or feedback
mechanisms. An alternative scenario that might be envisaged
for PROTAC molecules operating under a diﬀerent regime,
e.g., in a “slow-binding regime”, is that their association kinetics
might be suﬃciently rate limiting as to inﬂuence the ultimate
outcome of the target degradation.
We wished to examine these hypotheses in a cellular context.
Time-course studies were performed to measure initial rate of
degradation of Brd4, Brd3, or Brd2 in response to treatment of
HEK293 cells with MZ1 (Figure 4B; see Figure S11 for
representative Western blot data). We observed rapid
degradation of Brd2 and both isoforms of Brd4, while the
degradation of Brd3 was signiﬁcantly slower (Figure 4B and
Table S3). Recent results by an independent group, published
while this manuscript was in preparation, strongly support our
conclusion.19 Consistent with our data, Riching et al. observed
more rapid initial rates of degradation and greater levels of
ubiquitination for Brd2 and Brd4 compared to Brd3 in
response to MZ1 treatment.19 Crucially, we observed a
correlation between the half-life of the VHL/MZ1/BD2
ternary complexes and the initial rate of degradation of the
Figure 3. (A) Overlay of Brd2BD2 (PDB: 3ONI) and Brd3BD2 (PDB:
3S92) with the crystal structure of the VCB/MZ1/Brd4BD2 ternary
complex (PDB: 5T35) suggests that a VHL/MZ1/Brd3BD2 ternary
complex adopting the equivalent close-packing interaction would
likely be less stable due to steric clash with the VHL/MZ1 of a single
amino acid within the ZA loop of the bromodomain (Glu344 of
Brd3BD2, which corresponds to Gly386 in Brd4BD2). (B) Diagram of
point mutants generated to explore reciprocal swap of the amino acid
at this position. (C) Reciprocal exchange of this single Gly/Glu
residue in Brd4BD2 (i, iii) or Brd3BD2 (ii, iv) yields a corresponding
swap of the kinetic proﬁle in the resulting VHL/MZ1/BD ternary
complex SPR sensorgram. For each sensorgram, values shown
represent ﬁtted dissociation constants for ternary complex formation
(KD
ternary), dissociative half-life of the ternary complex (t1/2)
(calculated as t1/2 = ln2/koff) and cooperativity factor (α) (calculated
as α = KD
binary/KD
ternary).
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corresponding BET protein, with the more slowly degraded
BET protein (Brd3, ƛ = 4 × 103 min−1, cf. with Brd2 and Brd4,
which show ƛ between 13 and 18 × 103 min−1) being also the
one that exhibits the shortest-lived ternary complex (Figure
4B). This data is consistent with the rapid equilibrium
framework, with the more stable and more slowly dissociating
ternary complexes driving cellular protein degradation, and not
consistent with a slow-binding ternary complex model;4
indeed, MZ1/Brd3BD2 showed comparatively fast association
kinetics in our SPR data for binding to VHL (kon = 160 × 10
5
M−1 s−1), possibly even slightly faster as compared to MZ1/
Brd2BD2 and MZ1/Brd4BD2 (Table 1). Taken together, these
observations strongly suggest a mechanistic link between the
relative half-life of a given target/PROTAC/E3 ligase ternary
complex and initial rates of target degradation, which drives a
faster and more profound target depletion in cells, at least for
PROTACs operating under the “rapid equilibrium” kinetics
model such as the archetypical degrader MZ1 studied herein.
In conclusion, we demonstrate a simple and robust SPR-
based method to quantify for the ﬁrst time the stability of
target/PROTAC/ligase ternary complexes by measuring the
kinetics of their formation and dissociation. We demonstrate
that our surface-based SPR method yields values for aﬃnity,
cooperativity (α) and complex stability comparable to ITC in
solution2,10 with increased throughput and yielding additional
kinetic information not achievable using other assays described
to date. We show by SPR that a single residue can impart
signiﬁcant changes in cooperativity, stability, and dissociative
half-lives of ternary complexes formed with diﬀerent but highly
conserved target proteins. Lastly, we observe that these kinetic
diﬀerences of ternary complexes correlate to relative initial
rates of target degradation for the well-characterized BET
degrader MZ1. Together, these ﬁndings establish a new assay
for PROTAC ternary complex kinetics and illuminate on
ternary complex stability and dissociative half-lives as key
optimization parameters for PROTAC design and discovery
campaigns.
Our studies suggest that a potential challenge or limitation
of this approach is the requirement for moderate quantities of
whichever target protein is used in “near-saturating” concen-
trations; however, our experiments also suggest that mean-
ingful data may still be obtained using lower concentrations
than that generally used in this study (Figures S1 and S5). Our
data also suggest that it may be necessary to evaluate both
binding orientations (immobilizing either the target protein or
E3 ligase on the sensor surface) to ascertain which format
yields the best data. Nonspeciﬁc eﬀects exhibited by certain
PROTACs may also pose challenges in determining binary
dissociation constants. This notwithstanding, we anticipate
that our SPR kinetic assay will become an established tool to
drive PROTAC development and to further elucidate the
dynamic processes governing their mode of action. We
envision that one natural extension of our approach may be
adaptation to use in more high-throughput assays, in particular
due to the additional kinetic information it provides relative to
alternative binding approaches such as AlphaScreen or TR-
FRET. This is rendered more feasible by the availability of
newer highly parallel SPR instruments with improved
sensitivity, reducing sample consumption. In our described
approach, the E3 ligase (in this case, VHL) is immobilized on
the sensor surface, which has the advantage of being agnostic
of the target protein of interest; using this format, any target
protein (domain or full-length) might conceivably be used that
is capable of recombinant production. In suitable cases, a
reversed format using immobilized target protein might
provide certain beneﬁts, such as enabling the same
PROTAC/E3 ligase solution to be simultaneously screened
against both targets and anti-targets on parallel ﬂowcells.
Another possibility might be direct capture of over-expressed
full-length protein from cell lysate onto the sensor surface by
way of a suitable aﬃnity tag. Furthermore, immobilization of
the protein of interest may make this approach capable of
extension to screening for the most-suitable E3 ligase/
PROTAC complexes for forming stable and long-lived
complexes. Beyond PROTACs, this assay could also be
applied more broadly to study three-body binding equilibria
induced by other classes of heterobivalent molecules.30
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Figure 4. (A) Correlation between binary (MZ1) and ternary (MZ1/
BD complex) binding to VHL via SPR or FP (mean plus or minus the
standard deviation, SD). (B) Initial degradation proﬁle for BET
proteins in HEK293 cells in response to MZ1 treatment (333 nM),
with initial degradation rates (ƛ) estimated from data ﬁtting (mean
plus or minus the standard error of the mean, N = 3) and SPR ternary
half-lives for corresponding VHL/MZ1/BD2 complexes (mean ± SD
for N = 2). Note that short and long isoforms of Brd4 diﬀer in the
length of the C-terminus after the tandem bromodomains.29
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Tables showing ﬁtted SPR data, SPR and FP binding
studies, and ﬁtted degradation time-course data; ﬁgures
showing the selection of the PROTAC-to-target ratio,
lack of signiﬁcant interaction, data treatment, SPR
sensorgrams, the eﬀect of varying the PROTAC-to-
target ratio, reversed-format SPR binding experiments,
ﬁtted ﬂuorescence polarization competition data, and a
representative Western blot; additional details on
experimental methods (PDF)
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